Exonate fundraises £1.5 million
Exonate has successfully fundraised £1.5 million to accelerate development of its lead product - an eye drop treatment for retinal neovascular diseases.
The announcement marks the closing of its fourth financing round, having raised approximately £9 million in total to date, backed by investment from Angel CoFund, Australian venture fund Uniseed, University of Bristol Enterprise Fund, managed by Parkwalk, Martlet of Cambridge, Wren Capital, and O2h Ventures as well as further Angel investors.
The funds raised will be used to accelerate the development of Exonate’s lead product, an eye drop for the treatment of retinal neovascular diseases.
You can read the full story on the Pharma Times website here